c2bfde36-4ebd-48d7-8662-cf82253a3eab
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 50.0287474332649
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.380
- ANGIOGENESIS+0.310
- HEDGEHOG_SIGNALING+0.300
- TGF_BETA_SIGNALING+0.220
- NOTCH_SIGNALING+0.180
- PROTEIN_SECRETION+0.180
- MITOTIC_SPINDLE+0.170
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.120
- MYC_TARGETS_V1+0.110
- APICAL_JUNCTION+0.090
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.370
- ADIPOGENESIS-0.360
- INTERFERON_GAMMA_RESPONSE-0.350
- INTERFERON_ALPHA_RESPONSE-0.330
- OXIDATIVE_PHOSPHORYLATION-0.330
- IL6_JAK_STAT3_SIGNALING-0.270
- INFLAMMATORY_RESPONSE-0.270
- MYC_TARGETS_V2-0.270
- PANCREAS_BETA_CELLS-0.260
- TNFA_SIGNALING_VIA_NFKB-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613798 | — | D | 0.833 |
| 2 | ERR2208936 | — | — | 0.817 |
| 3 | ca7940e6-af7e-44fd-a6fc-5d86dc1d86c4 | — | — | 0.787 |
| 4 | TCGA-D8-A1XB-01A-11R-A14D-07 | — | A | 0.779 |
| 5 | TCGA-A1-A0SB-01A-11R-A144-07 | — | A | 0.778 |
| 6 | 20100144.Her2HRpos | — | D | 0.777 |
| 7 | TCGA-CQ-7072-01A-21R-A30B-07 | — | — | 0.776 |
| 8 | a7bda5b9-9c95-4f90-bab6-10ab15ee2b48 | — | — | 0.775 |
| 9 | 8a25dfb0-edd0-4a44-9a6b-8f3f761b940c | — | — | 0.774 |
| 10 | TCGA-98-8021-01A-11R-2247-07 | — | cohortSQ1 | 0.774 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.380 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.310 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.220 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.120 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.110 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.060 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.060 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.010 | Inavolisib | — uncovered |